Novartis multiple sclerosis product Gilenya approved in China

诺华多发性硬化症药物Gilenya获快速批准,将在中国上市

2019-07-24 10:00:00 PHARMACEUTICAL

本文共617个字,阅读需2分钟

Multiple sclerosis is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date[1]. Novartis is committed to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2017. Following the approval of Cosentyx in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China. “It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent® demonstrate our commitment to Chinese patients. We are proud that Gilenya already demonstrated its benefits to over 283,000 MS patients worldwide. We are committed to bringing innovation to China with our key brands Entresto, Cosentyx and now Gilenya.” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “I am delighted that we can now offer Gilenya to doctors and patients in China. There is a considerable need for MS treatments in China and we strive to bring clinical benefit to many patients with multiple sclerosis and improve their quality of life,” said Ingrid Zhang, President, Novartis Pharmaceuticals China.
多发性硬化症在中国被列为罕见疾病,在中国估计有3万多发性硬化症患者。 Gilenya是全球第三大处方MS疾病改良剂。今天, Gilenya被医生广泛认可,迄今已有28.3万名接受 Gilenya 治疗的患者[1]。 诺华(Novartis)致力于为中国带来创新,并为患者重新提供护理。Entesto ®于2017年获得批准。继Cosentyx于3月获得批准之后, Gilenya 是诺华(Novartis)公司在中国紧急需要的药品清单上批准的下一个关键产品。 “对于中国的多发性硬化症患者来说,这是一个令人兴奋的消息, Gilenya已经获得了快速批准。Gilenya的批准和即将到来的 Mayzent ®监管审查证明了我们对中国患者的承诺。我们感到自豪的是, Gilenya 已经向全世界283000多名 MS 患者展示了它的益处。我们致力于以我们的主要品牌 Entesto 、 Coentyx 和现在的 Gilenya 为中国带来创新。诺华(Novartis)制药总裁 Marie-France Tschudin 说。 “我很高兴我们现在能为中国的医生和患者提供 Gilenya 。诺华(Novartis)制药( Novartis Pharmaceuticals China )中国区总裁张英德( Ingrid Zhang )表示:“中国对 MS 治疗的需求很大,我们努力为许多多发性硬化症患者带来临床益处,改善他们的生活质量。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文